U.S. FDA approves Acadia's genetic Rett syndrome drug

The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's drug for the treatment of Rett Syndrome, a genetic brain disorder. The drug, to be sold under the brand name Daybue, is approved for adult and pediatric patients two years of age and older.

March 12, 2023 . 10:37 PM

1 min read

The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's drug for the treatment of Rett syndrome, a genetic brain disorder.
The drug, to be sold under the brand name Daybue, is approved for adult and pediatric patients two years of age and older.
The approval comes with a warning of diarrhea and weight loss.
Analysts have estimated a list price at launch of $450,000 annually and peak U.S. trofinetide sales of $487.2 million by 2035.
Acadia's drug acts as an artificial form of the insulin-like growth factor IGF-1 and helps reduces inflammation in the nervous tissue as well as aid in the transmission of nerve impulses.